Cell Therapeutics To Launch First Commercial Product Trisenox With 16 Reps

Cell Therapeutics will launch its first commercial product Trisenox for treatment of acute promyelocytic leukemia with an internal oncology sales force of 16 reps, CTI CEO James Bianco, MD, told a Sept. 27 conference call.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet